We must now take stock of the failure of traditional allergy treatments. Thousands of people still live under the deadly threat of anaphylaxis. Children with allergies have to deal with impaired sleep and the consequences on their ability to learn. The impact of allergy on work performance has been objectively documented. We all have to bear the socio-economic burden of ineffective remedies.
Desensitization involves the administration of small, gradually increasing amounts of allergenic extracts. This is still often referred to as “allergy shots”. Desensitization has long been a treatment of last resort because of the risk of allergic reaction (anaphylaxis) and the major inconvenience of repeated medical visits over several years.
The precise components (proteins) that cause an allergy in a given person are now known. Despite this, desensitization remains based on whole extracts of pollen, animal dander or crushed insects. These are relatively impure (heterogeneous) products whose protein composition remains quite variable.
What’s more, science now tells us that the answer to allergy lies beyond simply administering allergens alone. This scientific insight comes as today’s industry leaders are scrambling to adapt their desensitization products to contemporary regulatory standards.
ANGANY proposes instead to rely on an allergen bioparticle to help us control the allergic pandemic, one person at a time. ANGANY is developing a new generation of allergy products designed to elicit a protective response while also being quite safe.
ANGANY brings innovations that could mark a turning point in our fight against allergy.
Follow us as we soon bring these innovations to clinical development!